



MEDIA RELEASE

Changes to VivaZome's Executive and Board

- Ms Xenia Sango appointed as Chief Executive Officer (CEO) and Managing Director.
- Dr David Haylock appointed as Chief Scientific Officer (CSO).
- Dr Anthony Filippis appointed as Non-Executive Director.

4 September 2023 - Melbourne, Australia: VivaZome Therapeutics Pty Ltd ("VivaZome" or "Company") is pleased to announce a suite of changes to its Executive and Board.

Ms Xenia Sango has been promoted to the position of CEO and Managing Director from her current role as Chief Operating Officer, effective 1 September 2023. Xenia has been working with VivaZome from its inception and has a deep knowledge of all aspects of the Company's operations and aspirations. She has over 30 years' experience in biological therapies and clinical development, based on previous senior roles at CSL Limited and Epworth Health.

Dr David Haylock, who has held the CEO position since November 2019, will resume the position of CSO, a role he hitherto combined with his CEO responsibilities. In the CSO role, David will focus on driving the Company's science strategy and operations. David will also continue to work on identifying, securing and implementing enabling technologies, and on VivaZome's key research collaborations.

Dr Anthony Fillips, Chief Operating Officer at Antisense Therapeutics Ltd (ASX: ANP), joins the VivaZome Board as a Non-Executive Director. He brings a wealth of sector experience in executive leadership, operational management and fund-raising. Dr Filippis is a Director of Connectivity Traumatic Brain Injury Australia and, prior to Antisense, was CEO of Neurosciences Victoria.

VivaZome's Chairman, Dr Ian Nisbet, said "These changes enhance VivaZome's leadership team. We are delighted that Xenia has accepted the CEO position and congratulate her on the appointment. She is an excellent leader of people and programs and is well-placed to drive all aspects of our business including fund-raising and stakeholder engagement."

"We thank David for his exceptional leadership in the CEO role and are very pleased that he will continue to oversee and drive the science program at VivaZome. Amongst other achievements, David played a pivotal role in securing CRC-P funding and engaging key collaborators at The University of Queensland and Australian National University."

"Finally, we welcome Anthony to the Board and look forward to leveraging his experience, insights and global network to help refine the Company's strategic direction and expand its engagement with potential partners and investors."

For further information, contact:

Ms Xenia Sango, CEO, VivaZome Therapeutics Pty Ltd

Xenia.sango@vivazome.com

Phone + 61 (0) 406 180 812

About VivaZome:

VivaZome Therapeutics Pty Ltd is a privately-held Australian biotech company, with operational headquarters at La Trobe University in Melbourne, Australia. VivaZome aims to develop and commercialise exosome-based therapies for debilitating and/or life-threatening disorders, with an initial focus on neurological disorders, retinal disease and ischaemic conditions. VivaZome is developing new technologies and generating intellectual property that are applicable generically to exosome therapies. These will underpin the Company's development of specific exosome products for its target indications. The VivaZome team has extensive expertise in the development and commercialisation of biological therapies, together with a wide network of expert contacts in the Australian and global biotech community.

For more information, please visit www.vivazome.com